Fulminant onset of acute leukemia from normal hematopoiesis within 3 months of follow up for multiple myeloma treated with total therapy protocols

Por Singh, Zeba N, Jethava, Yogesh, Post, Ginell R, Alapat, Daisy, Sawyer, Jeffrey, Waheed, Sarah, Nair, Bijay, Usmani, Saad Z, Bailey, Clyde, Petty, Nathan, Van Rhee, Frits, Barlogie, Bart
Publicado no Clin Case Rep (2015)

Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma

Por Papanikolaou, Xenofon, Szymonifka, Jackie, Rosenthal, Adam, Heuck, Christoph J., Mitchell, Alan, Johann, Donald, Keller, Jason, Waheed, Sarah, Usmani, Saad Z., Van Rhee, Frits, Bailey, Clyde, Petty, Nathan, Hoering, Antje, Crowley, John, Barlogie, Bart
Publicado em 2013

Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120)

Por Khan, Rashid, Dhodapkar, Madhav, Rosenthal, Adam, Heuck, Christoph, Papanikolaou, Xenofon, Qu, Pingping, van Rhee, Frits, Zangari, Maurizio, Jethava, Yogesh, Epstein, Joshua, Yaccoby, Shmuel, Hoering, Antje, Crowley, John, Petty, Nathan, Bailey, Clyde, Morgan, Gareth, Barlogie, Bart
Publicado no Haematologica (2015)

Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1

Por Heuck, Christoph J, Szymonifka, Jackie, Hansen, Emily, Shaughnessy, John D., Usmani, Saad Z, van Rhee, Frits, Anaissie, Elias, Nair, Bijay, Waheed, Sarah, Alsayed, Yazan, Petty, Nathan, Bailey, Clyde, Epstein, Joshua, Hoering, Antje, Crowley, John, Barlogie, Bart
Publicado em 2012

Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma

Por Usmani, Saad Z., Sawyer, Jeffrey, Rosenthal, Adam, Cottler-Fox, Michele, Epstein, Joshua, Yaccoby, Shmuel, Sexton, Rachael, Hoering, Antje, Singh, Zeba, Heuck, Christoph J., Waheed, Sarah, Chauhan, Nabeel, Johann, Donald, Abdallah, Al-Ola, Muzaffar, Jameel, Petty, Nathan, Bailey, Clyde, Crowley, John, van Rhee, Frits, Barlogie, Bart
Publicado em 2013

Hyperhaploidy is a Novel High-Risk Cytogenetic Subgroup in Multiple Myeloma

Por Sawyer, Jeffrey R., Tian, Erming, Shaughnessy, John D., Epstein, Joshua, Swanson, Charles M., Stangeby, Collin, Hale, Christine L., Parr, Lewis, Lynn, Michael, Sammartino, Gael, Lukacs, Janet L., Stein, Caleb, Bailey, Clyde, Zangari, Maurizio, Davies, Faith E., Van Rhee, Frits, Barlogie, Bart, Morgan, Gareth J.
Publicado no Leukemia (2016)